A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

Neither the FDA nor EMA recognizes aging as an indication – but the drafts, the precedent and the people on record are ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

The Parkinson’s enzyme therapy is still heading toward the clinic, and the deal could grow by up to $1.17bn in milestone ...

Designerly's Cooper Adwin looks at why generative AI Is re-engineering skin rejuvenation and phasing out animal collagen.